iX has a portfolio of products in the pipeline for pain management, men's health and improved sleep quality.
Some of these products may be developed along the FDA's Sections 505(b)(2) and 505(j) approval process. These expedited regulatory pathways have the potential to allow iX to bring its products to market faster, with lesser risks and costs.
iX's lead therapeutic product is Wafermine™. Wafermine™ is the world's first sublingual ketamine oral wafer that contains the non-opioid drug for the management of moderate to severe pain. It is based on iX's proprietary WaferiX™ sublingual technology.
iX's next product in pain management is BnoX™. BnoX™ is a sublingual buprenorphine oral wafer that is developed as a formulation for moderate to severe pain. It is based on iX's proprietary WaferiX™ sublingual technology.
Pheonix™ is a product using sildenafil citrate as the approved active ingredient for the treatment of male erectile dysfunction.
Wafernyl™ is a sublingual wafer with fentanyl intended for breakthrough cancer pain (BTCP). Like Wafermine™ , Wafernyl™ enables the administration of the drug in a non-invasive way with ease and convenience compared to the standard use of intravenous injection (IV) for cancer patients.